NZ595775A - Fused imidazole derivatives as trpv3 antagonist - Google Patents
Fused imidazole derivatives as trpv3 antagonistInfo
- Publication number
- NZ595775A NZ595775A NZ595775A NZ59577509A NZ595775A NZ 595775 A NZ595775 A NZ 595775A NZ 595775 A NZ595775 A NZ 595775A NZ 59577509 A NZ59577509 A NZ 59577509A NZ 595775 A NZ595775 A NZ 595775A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pain
- disease
- vinyl
- nicotinonitrile
- imidazo
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 208000004296 neuralgia Diseases 0.000 abstract 2
- IQTVYDHNLZSCPM-ACCUITESSA-N 6-[2-[(e)-2-(2-butoxy-3-methoxyphenyl)ethenyl]imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile Chemical compound CCCCOC1=C(OC)C=CC=C1\C=C\C1=NC2=CC=CN=C2N1C1=CC=C(C#N)C=N1 IQTVYDHNLZSCPM-ACCUITESSA-N 0.000 abstract 1
- CSASCNRGJLQZED-ZRDIBKRKSA-N 6-[2-[(e)-2-(2-cyclopentyloxy-3-methoxyphenyl)ethenyl]imidazo[4,5-c]pyridin-1-yl]pyridine-3-carbonitrile Chemical compound C1CCCC1OC=1C(OC)=CC=CC=1\C=C\C1=NC2=CN=CC=C2N1C1=CC=C(C#N)C=N1 CSASCNRGJLQZED-ZRDIBKRKSA-N 0.000 abstract 1
- LBLALBKZCIQGMR-WYMLVPIESA-N 6-[2-[(e)-2-(3-methoxy-2-pentoxyphenyl)ethenyl]imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile Chemical compound CCCCCOC1=C(OC)C=CC=C1\C=C\C1=NC2=CC=CN=C2N1C1=CC=C(C#N)C=N1 LBLALBKZCIQGMR-WYMLVPIESA-N 0.000 abstract 1
- GBWLVWNMNBZKPW-ACCUITESSA-N 6-[2-[(e)-2-[2-cyclopentyloxy-3-(difluoromethoxy)phenyl]ethenyl]imidazo[4,5-b]pyridin-3-yl]pyridine-3-carbonitrile Chemical compound C1CCCC1OC=1C(OC(F)F)=CC=CC=1\C=C\C1=NC2=CC=CN=C2N1C1=CC=C(C#N)C=N1 GBWLVWNMNBZKPW-ACCUITESSA-N 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 206010058019 Cancer Pain Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000015943 Coeliac disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000004232 Enteritis Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020559 Hyperacusis Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000027530 Meniere disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000007101 Muscle Cramp Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000001294 Nociceptive Pain Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 208000004550 Postoperative Pain Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 206010060875 Uraemic pruritus Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 208000024780 Urticaria Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 208000003728 Vulvodynia Diseases 0.000 abstract 1
- 206010069055 Vulvovaginal pain Diseases 0.000 abstract 1
- 208000009621 actinic keratosis Diseases 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 231100000360 alopecia Toxicity 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000003925 brain function Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000000718 duodenal ulcer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 abstract 1
- 208000009326 ileitis Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 210000004165 myocardium Anatomy 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 208000037916 non-allergic rhinitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000001823 pruritic effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
- 206010044652 trigeminal neuralgia Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2705MU2008 | 2008-12-26 | ||
| US14686509P | 2009-01-23 | 2009-01-23 | |
| IN1732MU2009 | 2009-07-29 | ||
| US23743409P | 2009-08-27 | 2009-08-27 | |
| PCT/IB2009/008018 WO2010073128A2 (en) | 2008-12-26 | 2009-12-23 | Fused imidazole derivatives as trpv3 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595775A true NZ595775A (en) | 2013-07-26 |
Family
ID=42288192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595775A NZ595775A (en) | 2008-12-26 | 2009-12-23 | Fused imidazole derivatives as trpv3 antagonist |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8344010B2 (enExample) |
| EP (1) | EP2370425A4 (enExample) |
| JP (1) | JP2012514577A (enExample) |
| AU (1) | AU2009332651A1 (enExample) |
| CA (1) | CA2744911A1 (enExample) |
| EA (1) | EA201190086A1 (enExample) |
| GE (1) | GEP20146096B (enExample) |
| MX (1) | MX2011006821A (enExample) |
| NZ (1) | NZ595775A (enExample) |
| WO (1) | WO2010073128A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012129491A1 (en) * | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Trpv3 modulators |
| BR112017002598B1 (pt) | 2014-08-12 | 2022-03-03 | Syngenta Participations Ag | Derivados heterocíclicos ativos do ponto de vista pesticida com substituintes contendo enxofre |
| WO2017001314A1 (en) | 2015-07-01 | 2017-01-05 | Syngenta Participations Ag | Pesticidally active polycyclic derivatives with sulfur containing substituents |
| BR112018010347A2 (pt) | 2015-11-23 | 2018-12-04 | Syngenta Participations Ag | derivados heterocíclicos ativos em termos pesticidas com substituintes contendo enxofre e ciclopropila |
| CN105503737B (zh) * | 2016-01-25 | 2018-06-19 | 大连理工大学 | 一种无催化剂制备苯并咪唑类或苯并噻唑类化合物的方法 |
| WO2017134066A1 (en) | 2016-02-05 | 2017-08-10 | Syngenta Participations Ag | Pesticidally active heterocyclic derivatives with sulphur containing substituents |
| KR102454777B1 (ko) * | 2016-06-17 | 2022-10-14 | 드러그 딜리버리 솔루션즈 에이피에스 | 요독 가려움증의 치료에 사용하기 위한 제형 |
| AR118243A1 (es) | 2019-03-07 | 2021-09-22 | Pi Industries Ltd | Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas |
| US12612369B1 (en) | 2025-12-15 | 2026-04-28 | King Faisal University | Eco-friendly synthesis of a novel nicotinonitrile derivative (MNPN) with antibacterial and anti-inflammatory activities for preventing pressure ulcers in individuals with disabilities |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS625966A (ja) * | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | ベンズイミダゾ−ル誘導体 |
| US20040009537A1 (en) | 2002-01-11 | 2004-01-15 | Jack Roos | Methods of modulating and of identifying agents that modulate intracellular calcium |
| JP4448170B2 (ja) | 2004-08-18 | 2010-04-07 | ベッチャー・ローベルト | エノサル歯科インプラント |
| CA2589363A1 (en) | 2004-12-13 | 2006-06-22 | Eli Lilly And Company | Spiro derivatives as lipoxygenase inhibitors |
| EP1931681B1 (en) | 2005-10-07 | 2012-11-14 | Glenmark Pharmaceuticals S.A. | Substituted benzofused derivatives and their use as vanilloid receptor ligands |
| US20100152209A1 (en) | 2005-11-04 | 2010-06-17 | Hydra Biosciences Inc. | Compounds for Modulating TRPV3 Function |
| KR20080070749A (ko) | 2005-11-23 | 2008-07-30 | 페인셉터 파마 코포레이션 | 개폐 이온 통로를 조절하기 위한 조성물 및 방법 |
| WO2008033564A1 (en) | 2006-09-15 | 2008-03-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| EA201000675A1 (ru) | 2007-12-18 | 2011-06-30 | Гленмарк Фармасьютикалс, С.А. | Производные хромана как модуляторы trpv3 |
| GEP20125574B (en) * | 2008-01-11 | 2012-07-10 | Glenmark Pharmaceuticals Sa | Fused pyrimidine derivatives as trpv3 modulators |
| US8119647B2 (en) | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| US8318928B2 (en) * | 2008-12-15 | 2012-11-27 | Glenmark Pharmaceuticals, S.A. | Fused imidazole carboxamides as TRPV3 modulators |
-
2009
- 2009-12-23 NZ NZ595775A patent/NZ595775A/xx not_active IP Right Cessation
- 2009-12-23 WO PCT/IB2009/008018 patent/WO2010073128A2/en not_active Ceased
- 2009-12-23 AU AU2009332651A patent/AU2009332651A1/en not_active Abandoned
- 2009-12-23 JP JP2011542926A patent/JP2012514577A/ja active Pending
- 2009-12-23 MX MX2011006821A patent/MX2011006821A/es active IP Right Grant
- 2009-12-23 GE GEAP200912274A patent/GEP20146096B/en unknown
- 2009-12-23 EP EP09834200A patent/EP2370425A4/en not_active Withdrawn
- 2009-12-23 CA CA2744911A patent/CA2744911A1/en not_active Abandoned
- 2009-12-23 EA EA201190086A patent/EA201190086A1/ru unknown
- 2009-12-23 US US13/141,199 patent/US8344010B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20146096B (en) | 2014-05-27 |
| WO2010073128A3 (en) | 2012-06-07 |
| EP2370425A4 (en) | 2013-02-27 |
| WO2010073128A2 (en) | 2010-07-01 |
| MX2011006821A (es) | 2012-01-03 |
| EP2370425A2 (en) | 2011-10-05 |
| CA2744911A1 (en) | 2010-07-01 |
| JP2012514577A (ja) | 2012-06-28 |
| US8344010B2 (en) | 2013-01-01 |
| AU2009332651A1 (en) | 2011-12-01 |
| EA201190086A1 (ru) | 2012-06-29 |
| US20110257193A1 (en) | 2011-10-20 |
| AU2009332651A2 (en) | 2012-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595776A (en) | Chromane derivatives as trpv3 modulators | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| RU2017135541A (ru) | Гетероциклические амины и их применения | |
| NZ600801A (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
| Heffron et al. | The design and identification of brain penetrant inhibitors of phosphoinositide 3-kinase α | |
| NZ595777A (en) | Fused imidazole carboxamides as trpv3 modulators | |
| NZ597533A (en) | Apoptosis signal-regulating kinase inhibitors | |
| JP2012514577A5 (enExample) | ||
| JP2012526143A5 (enExample) | ||
| PE20090835A1 (es) | Derivados de quinazolina como inhibidores de la pi3 quinasa | |
| NZ592617A (en) | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | |
| WO2008128968A1 (en) | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | |
| WO2008073785A3 (en) | Phosphoinositide 3-kinase inhibitor compounds and methods of use | |
| NZ604004A (en) | Pyridone and aza-pyridone compounds and methods of use | |
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| MX347619B (es) | Polimorfos y sales de 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-p iperazinil] metil}-1,3-oxazol-2-il)-1h-indazol como inhibidores de pi3k para usarse por ejemplo en el tratamiento de trastornos respiratorios. | |
| WO2013141586A1 (en) | Novelpyridopyrimidine derivatives and use thereof | |
| MY162461A (en) | Substituted benzamide derivatives | |
| JP2010523562A (ja) | ピリド−２−イル縮合複素環式化合物ならびにその組成物および使用 | |
| EA200901572A1 (ru) | 3-(имидазолил)пиразоло[3,4-b]пиридины | |
| NO20080445L (no) | Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer | |
| US8344010B2 (en) | Fused imidazole derivatives as TRPV3 antagonist | |
| WO2016160938A1 (en) | N-(1,3-thiazol-2-yl)pyrimidine-5-carboxamides as trpv3 modulators | |
| JP2016514117A5 (enExample) | ||
| CA2887887C (en) | Pyrazolopyridine derivatives as ttx-s blockers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENP | Pct: late entry into national phase requested |
Effective date: 20111014 |
|
| LENP | Pct: late entry into national phase granted |
Effective date: 20111014 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 DEC 2016 BY FREEHILLS PATENT ATTORNEYS Effective date: 20131031 |
|
| LAPS | Patent lapsed |